Model-based impact and cost-effectiveness of cervical cancer prevention in sub-Saharan Africa

Vaccine
Jane KimInnocent Mutyaba

Abstract

Using population and epidemiologic data for 48 countries in sub-Saharan Africa, we used a model-based approach to estimate cervical cancer cases and deaths averted, disability-adjusted life years (DALYs) averted and incremental cost-effectiveness ratios (I$ (international dollar) per DALY averted) for human papillomavirus (HPV) vaccination of pre-adolescent girls. Additional epidemiologic data from Uganda and South Africa informed estimates of cancer risk reduction and cost-effectiveness ratios associated with pre-adolescent female vaccination followed by screening of women over age 30. Assuming 70% vaccination coverage, over 670,000 cervical cancer cases would be prevented among women in five consecutive birth cohorts vaccinated as young adolescents; over 90% of cases averted were projected to occur in countries eligible for GAVI Alliance support. There were large variations in health benefits across countries attributable to differential cancer rates, population size, and population age structure. More than half of DALYs averted in sub-Saharan Africa were in Nigeria, Tanzania, Uganda, the Democratic Republic of the Congo, Ethiopia, and Mozambique. When the cost per vaccinated girl was I$5 ($0.55 per dose), HPV vaccination was...Continue Reading

References

Jun 28, 2001·JAMA : the Journal of the American Medical Association·S J GoldieT C Wright
Sep 1, 2005·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Wolfgang Greiner
Jul 4, 2007·Vaccine·Sue J GoldieEduardo L Franco
Sep 5, 2007·Bulletin of the World Health Organization·Angela Oloo AkumuUlla K Griffiths
Feb 1, 2008·Bulletin of the World Health Organization·Lara J WolfsonJean-Marie Okwo-Bele
Aug 22, 2008·The New England Journal of Medicine·Jane J Kim, Sue J Goldie
Apr 3, 2009·The New England Journal of Medicine·Rengaswamy SankaranarayananKetayun A Dinshaw
Jun 25, 2010·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Myron J LevinUNKNOWN IMPAACT P1047 Protocol Team
Jul 20, 2010·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Mireia DiazJane J Kim
Jul 1, 2011·International Journal of Cancer. Journal International Du Cancer·Nicole G CamposSue J Goldie
Aug 6, 2011·Vaccine·Harrell W ChessonLauri E Markowitz
Nov 15, 2011·Best Practice & Research. Clinical Obstetrics & Gynaecology·Rengaswamy SankaranarayananJean-Marie Dangou

❮ Previous
Next ❯

Citations

Dec 18, 2013·Vaccine·Lynette A DennyF Xavier Bosch
May 7, 2015·International Journal of Cancer. Journal International Du Cancer·Nicole G CamposJane J Kim
Jul 2, 2016·Virusdisease·Damiano PizzolKajal D Chhaganlal
Mar 16, 2017·International Journal of Cancer. Journal International Du Cancer·Alex K MezeiGina S Ogilvie
Aug 26, 2018·International Journal of Gynaecology and Obstetrics : the Official Organ of the International Federation of Gynaecology and Obstetrics·Austin M OberlinCarla J Chibwesha
Jul 12, 2017·International Journal of Gynaecology and Obstetrics : the Official Organ of the International Federation of Gynaecology and Obstetrics·D Scott LaMontagneCathy Ndiaye
Apr 26, 2017·Expert Review of Anti-infective Therapy·Ralph-Sydney Mboumba BouassaLaurent Bélec
Jul 28, 2020·International Journal of Public Health·Saba AbidiPuneeta Ajmera
Jul 17, 2019·Gynecologic Oncology Reports·Ava S RungeKrishnansu S Tewari
Nov 7, 2021·International Journal of Cancer. Journal International Du Cancer·Jennifer C SpencerJane J Kim

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

HIV/AIDS-Related Malignancies

HIV/AIDS infection increases the risk of non-communicable diseases common in the aged including HIV/AIDS-related malignancies. Discover the latest research in HIV/AIDS-related malignancies.